Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches

In September last year, the company submitted the NDA to the FDA seeking approval for the product. Credit: luchschenF / Shutterstock. The US Food and

Sat­suma Phar­ma­ceu­ti­cals was hand­ed a com­plete re­sponse let­ter for its nasal mi­graine drug af­ter the agency found is­sues with the prod­uct’s chem­istry, man­u­fac­tur­ing and con­trols. No